Scientists test cannabis compound with popular Weight-Loss drugs
NCT ID NCT06648031
Summary
This early-stage study tested the safety and initial effects of a new formulation of cannabidiol (CBD) when given alone and in combination with common diabetes/weight-loss medications (GLP-1 agonists). It involved 148 overweight or obese adults, some with pre-diabetes or type 2 diabetes. The goal was to see if combining CBD with these drugs is safe and might improve blood sugar control and weight loss more than the drugs alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE2DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia
-
Canopy Clinical Sutherland
Miranda, New South Wales, 2228, Australia
-
Canopy Clinical Wollongong
Wollongong, New South Wales, 2500, Australia
-
Emeritus - Melbourne
Camberwell, Victoria, 3124, Australia
-
Emeritus - Sydney
Botany, New South Wales, 2019, Australia
-
Paratus Clinical Brisbane Pty Ltd
Herston, Queensland, 4006, Australia
-
Paratus Clinical Pty Ltd, Blacktown Trial Clinic
Blacktown, New South Wales, 2148, Australia
Conditions
Explore the condition pages connected to this study.